% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • formerblueguy formerblueguy Nov 25, 2012 1:33 PM Flag

    NY Times article

    Online version of todays times.... Langer featured...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • To go along with the info in the NYT article..Langer's companies... Found this info .. If anyone can comment more on any of these companies (how they are doing), please do so.

      Blend Therapeutics—Co-founder; member, Scientific Advisory Board. Launched 2012 to design and integrate drugs targeting distinct disease pathways.
      Moderna Therapeutics—Co-founder. Launched 2010 to develop drugs using technology platform enabling cells to express proteins without changing their genome or creating long term safety concerns.
      Kala Pharmaceuticals—Co-founder and member, Board of Directors. Launched 2009 to develop drugs capable of penetrating mucosal barriers for treatment of major diseases affecting the eyes, lungs, gastrointestinal tract, and female reproductive system.
      Living Proof—Co-founder; Chief Scientific Advisor; Member, Board of Directors. Launched 2008 as Andora to market hair care and other beauty products for women. On Oct. 11, announced actress Jennifer Aniston as the company’s co-owner and hair care spokesperson.
      Selecta Biosciences—Co-founder; Scientific Advisor. Launched 2008 to commercialize nanoparticle technology for therapeutic and prophylactic immune modulation.
      Seventh Sense Biosystems—Co-founder. Launched 2008 to develop painless, simplified and safe blood collection technology platforms.
      TARIS Biomedical—Co-founder. Launched 2008 to develop treatments for bladder diseases.
      BIND Biosciences—Co-founder, Director, and Chairman of Scientific Advisory Board. Launched 2007 to apply nanotechnology toward treatment of cancer and cardiovascular disease.
      T2 Biosystems—Co-founder. Launched 2006 to develop next-generation medical diagnostic products by combining nanotechnology and miniaturized magnetic resonance technology to provide rapid, accurate and portable diagnostics.
      Arsenal Vascular—Co-founder; Member, Board of Directors. Launched 2005 as Arsenal Medical to develop its AxioCore nanofiber drug delivery platform as well as therapeutic foams. Renamed 2011.
      InVivo Therapeutics—Co-founder; Member, Scientific Advisory Board. Launched 2005 to develop technologies for treating spinal cord injuries and neurotrauma.
      Pervasis Therapeutics—Co-founder. Launched 2004 to develop therapies for common vascular interventions. In April 2012, Shire disclosed plans to acquire the company for an undisclosed sum.
      Pulmatrix—Co-founder. Launched 2003 to develop an inhaled dry powder platform and advance a new inhaled therapeutics platform, iSPERSE (inhaled small particles easily respirable and dispersible).
      Momenta Pharmaceuticals—Co-founder. Launched in 2001 to develop complex generics, follow-on biologics and new drugs.
      MicroCHIPS—Co-founder; Member, Board of Directors. Launched 1999 to apply microreservoir technology first developed at MIT to a tech platform that incorporates long-term implant technologies and wireless communications.
      TransForm Pharmaceuticals—Co-founder. Launched 1999 to develop superior formulations and novel crystalline forms of drug molecules. Acquired 2005 for about $230 million by Johnson & Johnson.
      Advanced Inhalation Research (AIR)—Co-founder. Launched 1997 to develop drugs based on pulmonary drug delivery technologies jointly created at MIT and Penn State University. Acquired 1999 for more than $100 million by Alkermes.
      Sontra Medical—Co-founder; Scientific Consultant. Launched 1996 to develop technology in ultrasound and skin permeation methods used in transdermal science for therapeutic and diagnostic applications. Merged 2007 with Echo Therapeutics.
      Acusphere—Co-founder. Launched 1993 to develop an injectible suspension cardiovascular drug for detection of coronary artery disease.
      At present: David H. Koch Institute Professor at MIT, one of 14 to receive the institute’s highest faculty honor.

      Degrees: Cornell University, #$%$. in chemical engineering, 1970; MIT, Sc.D. in chemical engineering, 1974.

    • Feel great that In Vivo has someone like Dr. Langer on its board of directors-makes the success of their technology that much more likely--wish I could invest in T2 Biosystems-apparently only privately held

      Sentiment: Strong Buy

6.5943-0.1757(-2.60%)9:54 AMEDT